GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NT-0796

NT-0796

Company
Rezera (formerly NodThera Limited)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Trial details
  • Completed NCT NCT06129409

    Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease

    Not yet reported Rezera (formerly NodThera Limited) 67 participants Est. completion 2024-04-15 2 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT07055516

    Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

    Not yet reported Rezera (formerly NodThera Limited) 176 participants Est. completion 2026-05-27 11 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07220629

    Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

    Not yet reported Rezera (formerly NodThera Limited) 82 participants Est. completion 2026-08-21 9 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.